JP2021515544A - Ｅｒｂｂ３結合剤 - Google Patents

Ｅｒｂｂ３結合剤 Download PDF

Info

Publication number
JP2021515544A
JP2021515544A JP2020543213A JP2020543213A JP2021515544A JP 2021515544 A JP2021515544 A JP 2021515544A JP 2020543213 A JP2020543213 A JP 2020543213A JP 2020543213 A JP2020543213 A JP 2020543213A JP 2021515544 A JP2021515544 A JP 2021515544A
Authority
JP
Japan
Prior art keywords
seq
amino acid
antibody
region
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020543213A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021515544A5 (https=
JPWO2019175359A5 (https=
Inventor
ジェームズ ジョナサン フィンレー，ウィリアム
ジェームズ ジョナサン フィンレー，ウィリアム
Original Assignee
ウルトラヒューマン サーティーン リミテッド
ウルトラヒューマン サーティーン リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウルトラヒューマン サーティーン リミテッド, ウルトラヒューマン サーティーン リミテッド filed Critical ウルトラヒューマン サーティーン リミテッド
Publication of JP2021515544A publication Critical patent/JP2021515544A/ja
Publication of JP2021515544A5 publication Critical patent/JP2021515544A5/ja
Publication of JPWO2019175359A5 publication Critical patent/JPWO2019175359A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020543213A 2018-03-14 2019-03-14 Ｅｒｂｂ３結合剤 Pending JP2021515544A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1804094.9 2018-03-14
GBGB1804094.9A GB201804094D0 (en) 2018-03-14 2018-03-14 ERBB3 Binding agents
PCT/EP2019/056506 WO2019175359A1 (en) 2018-03-14 2019-03-14 De-immunised anti-erbb3 antibodies

Publications (3)

Publication Number Publication Date
JP2021515544A true JP2021515544A (ja) 2021-06-24
JP2021515544A5 JP2021515544A5 (https=) 2022-05-26
JPWO2019175359A5 JPWO2019175359A5 (https=) 2022-05-26

Family

ID=61972871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020543213A Pending JP2021515544A (ja) 2018-03-14 2019-03-14 Ｅｒｂｂ３結合剤

Country Status (9)

Country Link
US (2) US10975165B2 (https=)
EP (1) EP3765156A1 (https=)
JP (1) JP2021515544A (https=)
CN (1) CN111818972A (https=)
AU (1) AU2019233694A1 (https=)
CA (1) CA3092610A1 (https=)
GB (1) GB201804094D0 (https=)
SG (1) SG11202008513WA (https=)
WO (1) WO2019175359A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11970539B2 (en) * 2020-09-14 2024-04-30 Ichnos Sciences SA Antibodies that bind to IL1RAP and uses thereof
WO2022078490A1 (zh) * 2020-10-15 2022-04-21 上海翰森生物医药科技有限公司 抗erbb3抗体或其抗原结合片段及其医药用途
WO2023198138A1 (zh) * 2022-04-13 2023-10-19 上海翰森生物医药科技有限公司 抗体或其抗原结合片段及其医药用途
TW202432185A (zh) * 2022-10-28 2024-08-16 美商翰森生物有限責任公司 配體－細胞毒性藥物綴合物及其藥物用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523166A (ja) * 2010-04-09 2013-06-17 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ＥｒｂＢ３抗体
JP2014503181A (ja) * 2010-10-18 2014-02-13 メディアファーマ エス． アール． エル． ＥｒｂＢ３結合抗体
WO2014159915A1 (en) * 2013-03-14 2014-10-02 The Board Of Regents Of The University Of Texas System Her3 specific monoclonal antibodies for diagnostic and therapeutic use
JP2015517300A (ja) * 2012-05-02 2015-06-22 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ ヒト化ｐａｎ−ｈｅｒ抗体組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5752687B2 (ja) * 2009-08-21 2015-07-22 メリマック ファーマシューティカルズ インコーポレーティッド Ｅｒｂｂ３の外部ドメインに対する抗体およびその使用
CN105884900A (zh) * 2011-04-19 2016-08-24 梅里麦克制药股份有限公司 单特异性和双特异性抗igf-1r和抗erbb3抗体
US10647756B2 (en) * 2015-05-18 2020-05-12 Pfizer Inc. Humanized antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523166A (ja) * 2010-04-09 2013-06-17 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ＥｒｂＢ３抗体
JP2014503181A (ja) * 2010-10-18 2014-02-13 メディアファーマ エス． アール． エル． ＥｒｂＢ３結合抗体
JP2015517300A (ja) * 2012-05-02 2015-06-22 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ ヒト化ｐａｎ−ｈｅｒ抗体組成物
WO2014159915A1 (en) * 2013-03-14 2014-10-02 The Board Of Regents Of The University Of Texas System Her3 specific monoclonal antibodies for diagnostic and therapeutic use

Also Published As

Publication number Publication date
US20200339702A1 (en) 2020-10-29
WO2019175359A1 (en) 2019-09-19
SG11202008513WA (en) 2020-10-29
EP3765156A1 (en) 2021-01-20
CN111818972A (zh) 2020-10-23
CA3092610A1 (en) 2019-09-19
US20210189003A1 (en) 2021-06-24
US10975165B2 (en) 2021-04-13
GB201804094D0 (en) 2018-04-25
AU2019233694A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
US12173067B2 (en) C-KIT antibodies and method for treating cancer with such
JP2021519100A (ja) Ｃｄ４７結合剤
US12415861B2 (en) Anti C-MET antibodies
JP2021515541A (ja) Ｐｄ１結合剤
JP7419238B2 (ja) Ｐｄ１結合剤
JP7689116B2 (ja) Ｐｄ１およびｖｅｇｆｒ２二重結合剤
US10975165B2 (en) De-immunised anti-ERBB3 antibodies
US11655300B2 (en) Colony stimulating factor 1 receptor (CSF1R) antibodies and immunoconjugates thereof
HK40100558A (zh) C-kit结合剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220428

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230907